Deal Brings Investors $100M Up Front
Shire's $325M FerroKin Buy Validates Iron Chelator Drug
By Marie Powers
Friday, March 16, 2012
Ireland's Shire plc bulked up its hematology business by scooping up small biotech FerroKin BioSciences Inc. for $100 million in up-front cash, plus potential milestone payments of up to $225 million based on achieving clinical development, regulatory and net sales targets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.